Form 4: Amicus Therapeutics CEO Sells Shares Under 10b5-1 Plan

Amicus Therapeutics President and CEO, Bradley L. Campbell, exercised stock options and subsequently sold 75,000 shares of common stock under a pre-arranged trading plan.

Summary

• Bradley L. Campbell, President and CEO, and a Director of Amicus Therapeutics, Inc. (FOLD), reported transactions on January 20, 2026.
• Campbell exercised 75,000 stock options at an exercise price of $6.10 per share.
• Concurrently, Campbell sold 75,000 shares of common stock at a weighted average price of $14.3091 per share, with prices ranging from $14.30 to $14.32.
• All transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on September 12, 2025.
• Following these transactions, Campbell directly beneficially owns 1,021,180 shares of Amicus Therapeutics common stock.
• The stock options exercised were fully vested and exercisable as of the transaction date, with an expiration date of June 15, 2026.

Sentiment

Score: 5

Explanation: A routine insider transaction involving the exercise of vested options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan. This is generally considered neutral as it's a planned event for personal liquidity/diversification rather than a signal of new information.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating they were pre-scheduled and not based on immediate, non-public information.
• The CEO realized a significant profit from exercising options at $6.10 and selling shares at an average of $14.3091.
• Bradley L. Campbell retains a substantial direct beneficial ownership of 1,021,180 shares, demonstrating continued alignment with shareholder interests.

Negatives

• Insider selling, even under a pre-arranged plan, can sometimes be interpreted by investors as a signal of reduced conviction in the company's near-term stock price appreciation.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports a routine insider transaction and does not provide information directly related to broader industry trends or competitive landscape for Amicus Therapeutics.

Related Party Transactions

• The reported transactions involve the President and CEO of Amicus Therapeutics, Bradley L. Campbell, exercising stock options and selling common stock, which are considered related party transactions due to his executive position.

Stakeholder Impact

• Shareholders: The transaction is a routine insider sale under a 10b5-1 plan, which typically has minimal direct impact on other shareholders. The CEO still holds a significant stake.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Keywords

Amicus Therapeutics, FOLD, Insider Trading, Form 4, Stock Options, CEO, Share Sale, 10b5-1 Plan